Cargando…
Highlights of ASS234: a novel and promising therapeutic agent for Alzheimer’s disease therapy
There is no effective treatment to face Alzheimer’s disease complexity. Multitarget molecules are a good approach against the multiple physiopathological events associated with its development and progression. In this context, N-((5-(3-(1-benzylpiperidin-4-yl) propoxy)-1- methyl-1H-indol-2-yl)methyl...
Autores principales: | Romero, Alejandro, Marco-Contelles, José, Ramos, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862399/ https://www.ncbi.nlm.nih.gov/pubmed/31535639 http://dx.doi.org/10.4103/1673-5374.262679 |
Ejemplares similares
-
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy
por: Marco-Contelles, José, et al.
Publicado: (2016) -
Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy
por: Pachón-Angona, Irene, et al.
Publicado: (2019) -
Melatonin and Nitrones As Potential Therapeutic Agents for Stroke
por: Romero, Alejandro, et al.
Publicado: (2016) -
Corrigendum: Melatonin and Nitrones As Potential Therapeutic Agents for Stroke
por: Romero, Alejandro, et al.
Publicado: (2017) -
Tailoring the Antibody Response to Aggregated Aß Using Novel Alzheimer-Vaccines
por: Mandler, Markus, et al.
Publicado: (2015)